FDA advisers vote against Delcath's cancer therapy
May 2 (Reuters) - A panel of advisers to the U.S. health regulator said that risks outweighed the benefits in Delcath Systems Inc's cancer therapy for a rare form of eye cancer that spreads to the liver.
The panel of independent experts voted 16-0 against the drug/device combination.
The drug-device combination product consists of a chemotherapy drug, melphalan hydrochloride, and a device known as the Delcath Hepatic Delivery System. The two are combined in a single package known as the Melblez Kit.